SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Amgen gets a full approval for Imdelltra
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
